Dronabinol

Dronabinol
Clinical data
Trade namesMarinol, Syndros
Other names(−)-trans-Δ9-tetrahydrocannabinol
License data
Dependence
liability
Physical: Low
Psychological: Low–moderate
Addiction
liability
Relatively low
Routes of
administration
By mouth
Drug classCannabinoid
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityPOTooltip Oral administration: 6–20%
Onset of actionPO: 0.5–1 hour
Elimination half-life25–36 hours
Duration of actionPO: 4–6 hours
Identifiers
  • (6aR,10aR)-6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
FormulaC21H30O2
Molar mass314.469 g·mol−1
3D model (JSmol)
Specific rotation−152° (ethanol)
Boiling point155–157 °C (311–315 °F) 0.05mmHg, 157–160°C @ 0.05mmHg
Solubility in water0.0028 mg/mL (23 °C)
  • CCCCCc1cc(c2c(c1)OC([C@H]3[C@H]2C=C(CC3)C)(C)C)O
  • InChI=1S/C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h11-13,16-17,22H,5-10H2,1-4H3/t16-,17-/m1/s1 Y
  • Key:CYQFCXCEBYINGO-IAGOWNOFSA-N Y

Dronabinol (INNTooltip International Nonproprietary Name), sold under the brand names Marinol and Syndros, is the generic name for the molecule of (−)-trans-Δ9-tetrahydrocannabinol (THC) in the pharmaceutical context. It has indications as an appetite stimulant, antiemetic, and sleep apnea reliever and is approved by the US Food and Drug Administration (FDA) as safe and effective for HIV/AIDS-induced anorexia and chemotherapy-induced nausea and vomiting.

Dronabinol is the principal psychoactive constituent enantiomer form, (−)-trans9-tetrahydrocannabinol, found in Cannabis sativa L. plants, but can also be synthesized in laboratory. Dronabinol does not include any other tetrahydrocannabinol (THC) isomers or any cannabidiol (CBD).